Concepedia

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

Joseph B. Domachowske, Yue Chang, Victoria Atanasova, Fernando Cabañas, Kenji Furuno, Kim An Nguyen, Irfana Banu, Amanda Leach, Vaishali S. Mankad, Manish Shroff,

Journal of the Pediatric Infectious Diseases Society · 2023 · 33 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.

References

4

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

New England Journal of Medicine · 2022 · 976 citations · Full text

, , +16

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

M. Pamela Griffin, Yuan Yuan, Therese Takas et al. · New England Journal of Medicine · 2020 · 747 citations · Full text

, , +13

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

Eric A. F. Simões, Shabir A. Madhi, William J. Muller et al. · The Lancet Child & Adolescent Health · 2023 · 318 citations · Full text

, , +15

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

M. Pamela Griffin, Anis A. Khan, Mark T. Esser et al. · Antimicrobial Agents and Chemotherapy · 2016 · 146 citations · Full text

, , +15